Agios Pharmaceuticals (FRA:8AP) FFO


FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
44 GF Score
Price €32.00
GF Value €73.32
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

FRA:8AP
44GF Score
Agios Pharmaceuticals Inc FRA:8AP
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €32.00 is trading 56.4% below its estimated GF Value™ of €73.32. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:8AP:

  • FFO:
  • GF Value™: €73.32 vs. price of €32.00 (56.4% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score

Get the complete analysis for FRA:8AP

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00
Price
€73.32
GF Value